Abstract Background: Andexanet alfa, a Gla-domainless mutant factor Xa (GDXa), reverses oral FXa inhibitors but can cause severe heparin resistance during cardiopulmonary bypass (CPB). Antithrombin (AT) supplementation may mitigate this..
Read More
Abstract Heparin is the primary anticoagulant used for cardiopulmonary bypass and requires reversal to prevent postoperative bleeding. Protamine sulfate is the only United States Food and Drug Administration–approved heparin reversal..
Read More
Andexanet Alfa–Associated Heparin Resistance in Cardiac Surgery: Mechanism and In Vitro Perspectives
Abstract BACKGROUND: Andexanet alfa (andexanet) is the only Food and Drug Administration–approved antidote for direct FXa (factor Xa) inhibitors but has been reported to cause resistance to unfractionated heparin (UFH)...
Read More
Abstract Thrombus occlusion in the cardiopulmonary bypass (CPB) circuit is a life-threatening adverse event. Herein, the authors present a case of Stanford type A aortic dissection in which the CPB..
Read More
Abstract Andexanet alfa is an analog of activated factor X and is used as an antagonist of anti-activated factor X agents. Andexanet alfa is useful for hemostasis in emergent bleeding..
Read More
Abstract Case Report A 72-year-old man with a tachycardiomyopathy, atrium flutter, and atrial fibrillation underwent an elective radiofrequency ablation procedure. In addition to 5 mg of apixaban twice daily, his..
Read More